

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049576 A1

(51) International Patent Classification⁷: **C07D 217/14**,
217/22, A61K 31/472, A61P 35/00

(21) International Application Number:
PCT/EP2004/013075

(22) International Filing Date:
17 November 2004 (17.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326964.4 19 November 2003 (19.11.2003) GB

(71) Applicant (for all designated States except US): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WASHIO, Yoshiaki**
[JP/JP]; Tsukuba Research Labs, 43 Wadai, Tsukuba-shi,
Ibaraki 300-4247 (JP).

(74) Agent: **LEAROYD, Stephanie, Anne**; GlaxoSmithKline,
Corporate Intellectual Property (CN925.1), 980 Great West
Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATH-
EROSCLEROSIS**



(I)

(57) Abstract: A compound of Formula (I) wherein: One of R¹ and R² is H and the other repre-
sents -NHCONHR⁴ wherein R⁴ represents a phenyl or naphthyl group (which may be optionally
substituted by one or more substituents independently selected from -C₁₋₆ alkyl, -C₁₋₆ haloalkyl,
-CH₂CH₂CH₂-, halogen, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, OH, NO₂), C₃₋₇ cycloalkyl or R⁴ together
with the NH to which it is bonded forms a morpholino group and R³ is H or NHR⁵ wherein
R⁵ is H, -quinolinyl or -isoquinolinyl, -(CONH)_p phenyl (wherein p is 0 or 1 and the phenyl is
optionally substituted by one or more substituents independently selected from halogen, -C₁₋₆
alkyl, -C₁₋₆ haloalkyl, -morpholino, -SO₂NH₂, benzothiazole (substituted by methyl)) or a salt,
solvate, or physiologically functional derivative thereof.